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Aims Differentiation of heart failure with reduced (HFrEF) or preserved (HFpEF) ejection fraction independent of
echocardiography is challenging in the community. Diagnostic strategies based on monitoring circulating microRNA
(miRNA) levels may prove to be of clinical value in the near future. The aim of this study was to identify a novel
miRNA signature that could be a useful HF diagnostic tool and provide valuable clinical information on whether a
patient has HFrEF or HFpEF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
MiRNA biomarker discovery was carried out on three patient cohorts, no heart failure (no-HF), HFrEF, and HFpEF,
using Taqman miRNA arrays. The top five miRNA candidates were selected based on differential expression in HFpEF
and HFrEF (miR-30c, −146a, −221, −328, and −375), and their expression levels were also different between HF
and no-HF. These selected miRNAs were further verified and validated in an independent cohort consisting of 225
patients. The discriminative value of BNP as a HF diagnostic could be improved by use in combination with any of the
miRNA candidates alone or in a panel. Combinations of two or more miRNA candidates with BNP had the ability
to improve significantly predictive models to distinguish HFpEF from HFrEF compared with using BNP alone (area
under the receiver operating characteristic curve >0.82).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in
the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of
natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords MicroRNA • Heart failure • Ejection fraction • Natriuretic peptide • Biomarker • Diagnosis
Translational perspective
Diagnosis of heart failure (HF) remains challenging. HF with pre-
served ejection fraction (HFpEF) and reduced ejection fraction HF
(HFrEF) cannot be readily differentiated on clinical grounds but
requires additional imaging tests, which are not frequently used in
patients with a community diagnosis.We identified a simple reverse
transcription–PCR (RT–PCR)-based biomarker approach improv-
ing diagnosis of HFpEF vs. HFrEF. Correct identification will be
important as there is a great need for stratifying HF patient cohorts
*Corresponding author: Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany. Tel:
+49 511 532 5272, Fax: +49 511 532 5274, Email: thum.thomas@mh-hannover.de
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.. for different management and potential novel future upcoming
treatment regimes.
Introduction
Heart failure (HF) has reached epidemic proportions, affecting
∼1–3% of the population within European countries, amounting
to 15 million people.1 The syndrome is characterized by significant
morbidity and reduced life expectancy, with 5-year mortality of
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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newly diagnosed HF as high as 50%2 and 10-year survival of 26.7%.3
Effective management of HF depends on an accurate and rapid
diagnosis. Currently, this requires assessment of symptoms and
physical signs in combination with advanced and expensive imaging
of cardiac structure and function. Symptom-based diagnostic chal-
lenges occur as co-morbidities of HF have similar presentations,
and practical challenges are posed by the fact that the majority
of HF cases are found in the community setting, where imaging
equipment and expertise are not readily available.4 In addition,
it has been well demonstrated that HF with preserved ejection
fraction (HFpEF) and HF with reduced ejection fraction (HFrEF)
cannot be readily differentiated on clinical grounds and requires
assessment by these imaging tests.5 This barrier to effective diag-
nosis and work-up of heart failure is underscored by data from
the UK indicating that more than half of patients with a com-
munity diagnosis of HF do not have echocardiography performed
and therefore have a ‘questionable diagnosis’.6 Having the ability
to diagnose HF more confidently within the community and to
be able to differentiate between HFpEF and HFrEF would be of
significant clinical value as the management of these conditions
differs and patients could be more readily triaged while waiting
for extensive clinical work-up within the cardiology department
in hospitals.
Given that the emerging opinion is that the pathophysiology
of HFpEF and HFrEF is different,7 it provides an opportunity to
identify biomarker candidates that could aid in HF diagnosis and
stratification between these two forms of the disease. Natriuretic
peptide (NP) is an effective diagnostic biomarker used to support
the diagnosis of HF in the community and is generally accepted
to be the most effective biomarker for this purpose presently
available.8,9 However, despite its widespread clinical use, NP is
still encumbered by reduced specificity, and, furthermore, while
modest differences have been shown to exist between HFrEF
and HFpEF, it does not behave in a significantly distinct man-
ner to allow accurate differentiation of these subtypes of heart
failure.10,11 Therefore a novel biomarker approach is required
instead of or to work in tandem with NP. The aim of this project
was to identify a novel circulating biomarker signature that could
be used either alone or in conjunction with established diagnostic
tests such as NPs, to identify HF and help differentiate HFpEF
and HFrEF. Unlike other studies, we focused on the analysis of
circulating microRNAs (miRNAs) which comprise a class of small,
non-coding RNAs that control expression of complementary
target mRNAs. Altered miRNA expression patterns have been
shown to reflect pathological processes including those which
are cardiovascular related, and have a realistic potential to serve
as diagnostic biomarkers in these diseases.12,13 The discovery of
altered disease-specific miRNA signatures that could be used as
a novel diagnostic biomarker test for HF classification have yet to
be defined. These could be used either alone or in combination
with current diagnostic tests, including NPs, to improve diagnos-
tic accuracy. Disease-specific miRNA signatures may also provide
insight into underlying disease mechanisms and pose as therapeutic
targets. ..
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Patient population
The total study population involved 270 patients from St. Vincent’s
University Hospital, Dublin. This population consisted of 90 HFpEF,
90 HFrEF, and 90 asymptomatic patients (no-HF) with cardiovascular
risk factors for future heart failure development. The asymptomatic
patients were recruited from the STOP-HF programme (The St Vin-
cent’s Screening to Prevent Heart Failure Study), which has recently
been described in detail.14 The 180 stable HF patients were recruited
from the Heart Failure Unit.
To be eligible for inclusion in the no-HF cohort, patients must have
been deemed asymptomatic following assessment at the time of pre-
sentation by an experienced attending cardiologist and were required
to have had an EF ≥50% at echocardiography. This population were
aged ≥40 years and had at least one risk factor for LV dysfunction
including type 2 diabetes mellitus (DM), hypertension, obesity, hyperc-
holesterolaemia, orCAD.
To be eligible for inclusion in the HFpEF cohort, patients were
required to have had a hospitalization for proven NYHA class IV HF
(confirmed by an attending cardiologist), continued symptoms of at
least NYHA class II HF, and an LVEF ≥50% with Doppler abnormalities
of diastolic dysfunction but no Doppler echocardiographic evidence of
significant valvular heart disease. The HFrEF cohort also had to have a
prior hospitalization for HF with an LVEF <50% and continued to have
at least NYHA class II symptoms.
All subjects gave written informed consent to participate in the
study. The study protocol was approved by the ethics committee of
St. Vincent’s University Hospital, which conformed to the principles of
the Declaration of Helsinki.
Clinical assessment
All study patients underwent a full history and physical examination,
NYHA functional class assessment, and phlebotomy. Physical examina-
tion included assessment of waist circumference, calculation of body
mass index (BMI), and heart rate and blood pressure measurement.
Peripheral venous blood samples were tested for levels of creatinine,
glucose, and lipid profile. Point of care BNP was measured using a
Triage meter (Biosite). Assay sensitivity for BNP was 5 ng/mL. Serum
samples were obtained from venous blood following clot formation and
centrifugation at 2500 g for 10min. Samples were aliquoted and stored
at −80 ∘C until required. All patients had Doppler echocardiography
performed.
Doppler echocardiography
Doppler echocardiographic assessment was performed by one of
two blinded operators in accordance with the European Society of
Echocardiography recommendations. All data represent the mean of
three measurements on sequential cardiac cycles. The LV mass was
calculated using the Devereux method and was indexed to body
surface area. Left atrial volume was calculated using the biplane area
length method and was also indexed to body surface area. The LV
filling pressures were non-invasively assessed with tissue Doppler
measurements taken at the lateral mitral annulus. The LVEF was
calculated by the Teichholz method.
Classification of LV diastolic dysfunction was based on having either
a left atrial volume index (LAVI) ≥34mL/m2 or a tissue lateral e’ value
≤10 cm/s.15
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Patient characteristics per study group
Variables No-HF (n= 75) HFpEF (n= 75) HFrEF (n= 75) P-values
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 72± 9 75± 7 70±11 0.008‡
Male, % 44 (59%) 46 (61%) 55 (73%) 0.15
SBP, mmHg 136± 20 124± 21 116± 21 <0.001*†
DBP, mmHg 81±13 74±12 70±10 <0.01* <0.001†
Heart rate, b.p.m. 67± 10 70±13 67±13 0.45
Body mass index, kg/m2 28± 4 31± 6 28± 4 <0.001*‡
Hypertension, % 60 (80%) 63 (84%) 25 (33%) <0.001†‡
Diabetes mellitus, % 14 (19%) 23 (31%) 11 (15%) 0.02‡
Dyslipidaemia, % 47 (63%) 47 (63%) 56 (75%) 0.20
Ischaemic heart disease, % 19 (25%) 35 (47%) 48 (64%) 0.007* <0.001† 0.03‡
Atrial fibrillation, % 9 (12%) 60 (80%) 43 (57%) <0.001*† 0.003‡
BNP, pg/mL 32 (15–70) 215 (126–353) 139 (71–254) <0.001*† <0.05‡
Medications
ACE inhibitor or ARB, % 47 (63%) 52 (70%) 68 (91%) <0.001†‡
Beta-blocker, % 28 (37%) 65 (87%) 60 (80%) <0.001*†
Calcium channel blocker, % 24 (32%) 24 (32%) 4 (5%) <0.001†‡
Diuretic, % 32 (43%) 70 (93%) 55 (73%) <0.001*† 0.002‡
Statin, % 51 (68%) 46 (61%) 51 (68%) 0.61
Antiplatelet, % 43 (57%) 38 (51%) 46 (61%) 0.41
Warfarin, % 5 (7%) 23 (31%) 29 (39%) <0.001*†
Echocardiography
Ejection fraction, % 66± 9 62± 7 36±12a <0.05* <0.001†‡
Interventricular septum, mm 11.5±1.9 12.6± 2.7 11.5± 3.0 0.06
Posterior wall, mm 9.9±1.5 11.0± 2.2 9.7± 2.2 <0.01*‡
LVMI, g/m2 95± 24 114± 36 126± 38 <0.01* <0.001†
LAVI, mL/m2 30± 11 52±19 46±14 <0.001*†
Deceleration time, ms 193± 46 215± 63 235± 84 0.004†
e′ (lat), cm/s 8.3± 2.7 9.6± 2.2 8.1± 3.7 <0.05*‡
Peak E, cm/s 70± 18 99± 24 66± 23 <0.001*‡
E/e′ ratio 9.0± 3.1 11.1± 3.6 9.6± 4.9 0.008*
Values are mean± SD, n (%), or median (interquartile range).
P-values for numerical variables are obtained from one-way analysis of variance with Bonferroni post-hoc analysis.
P-values for categorical variables are obtained from contingency 𝜒2 or Fisher’s test of the three study groups.
DBP, diastolic blood pressure; E/e’, ratio of mitral early diastolic flow velocity over tissue Doppler lateral mitral annular lengthening velocity; HF, heart failure; HFpEF, heart
failure with preserved ejection fraction, HFrEF, heart failure with reduced ejection fraction; LAVI, left atrial volume index; LVMI, left ventricular mass index; SBP systolic blood
pressure.
*, † , and ‡ indicate significant differences between no-HF and HFpEF, no-HF and HFrEF, and HFpEF and HFrEF groups, respectively.
aEjection fraction values recorded at the time of diagnosis of HFrEF.
MicroRNA analysis
Biomarker discovery and independent validation
Total RNA was extracted from 100 μL of serum collected from each of
the 270 study patients (three patient cohorts representing n= 90 per
group of no-HF, HFrEF, and HFpEF) using a Qiagen miRNeasy 96 kit as
per the manufacturer’s instructions.
A miRNA expression analysis was initially carried out on the three
patient cohorts with samples pooled from n=15 per group using
Taqman array Human MicroRNA card set v3 (Applied Biosystems, Life
Technologies #4444913) which has a 745 microRNA Taqman probe on
a 384-well microfluidic card (Applied Biosystems). MiRNAs with fold
change ≥2 compared with no-HF and those which could differentiate
HFpEF and HfrEF were selected, and among them top candidates with
higher fold change and expression were selected for validation. Array
data were analysed using Data Assist software. Five miRNA candidates
that showed potential as a HF diagnostic that could differentiate HFpEF ..
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.. and HFrEF were selected and further verified in the same patient
population using Taqman miRNA assays (Applied Biosystems). The
diagnostic utility of the five selected miRNAs was then further validated
in the remaining 225 patients (n= 75 per group).
Statistical analysis
All analyses were carried out using R statistical software version
2.7.2. The four outcomes tested were (i) HF present/absent; (ii)
HFpEF/HFrEF (within an HF-present subsample); (iii) EF; and (iv) LAVI.
The first two (binary) outcomes were analysed using Generalized
Linear Modelling with a binomial outcome; the latter two outcomes
were analysed using ordinary linear regression with transformations.
For each miRNA, the initial process of analysis was as follows: (i)
run the single variable linear model; (ii) run the same model adjusted
for BNP (log-transformed); (iii) run the same model adjusted for age
and gender; and (iv) run the same model adjusted for age, gender, and
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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BNP. For the binary outcomes, the area under the curve (AUC) is
reported as a measure of fit, and for the continuous outcomes, the R2
is reported. Each of the models tested in steps (ii), (iii), and (iv) above
were then compared with the unadjusted model using a 𝜒2 test on gain
in residual sum of squares per additional degree of freedom.
All miRNA values were log-transformed prior to analysis and missing
values were handled using listwise deletion—only patients with zero
non-missing data are included in the models.
Results
Patient population
The patient population is described in Table 1. All three populations
have a mean age >70 years old and had an equivalent gender
balance. The average systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were higher in the no-HF control group
compared with both HF cohorts. This is possibly reflective of
different medication usage between the three populations. The
HFpEF cohort demonstrates many of the typical characteristics of
this HF subtype, being marginally older than the other two cohorts,
having a greater BMI, and a high prevalence of hypertension and AF.
The HFrEF cohort also demonstrates typical characteristics with
dominant ischaemic aetiology. The NP levels are elevated in both
HF cohorts as one would anticipate. The lower level of NP in the
HFrEF group compared with the HFpEF group might be explained
by the impact of effective use of disease-modifying therapy in the
HFrEF cohort. Echocardiographic findings are again typical of these
groups with normal EF and markedly increased left atrial size in the
HFpEF cohort, though this measurement is probably influenced by
AF in many of this group. Both HF groups exhibit an increase in LV
mass compared with the control group.
Biomarker discovery for heart failure
diagnostics using a global microRNA
profiling approach
We performed miRNA profiling from the plasma RNA pool of
the discovery cohort and found several miRNAs which can dif-
ferentiate between the three groups (Figure 1). Five miRNA candi-
dates, miR-30c, miR-146a, miR-221, miR-328, and miR-375, were
selected from the miRNA screen carried out using the discovery
cohort based on high expression levels and high discriminatory
capacity. These selected miRNA candidates showed potential utility
as biomarkers that could differentiate between HFpEF and HFrEF
populations (Figure 1).
Independent validation of the five
selected microRNA candidates as heart
failure diagnostics
An independent cohort of an additional 225 patients consisting
of 75 no-HF, 75 HFpEF, and 75 HFrEF (clinical characteristics
described in Table 1) was used to validate the differential expression
patterns of the five selected miRNA candidates and to determine
whether they had any potential value as HF diagnostics, including ..
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.. the ability to differentiate between HFpEF and HFrEF. Graphical
representation of the expression levels of the five miRNA candi-
dates measured within the independent validation cohort is illus-
trated in Figure 2. In all cases, the average level of the miRNAs
was significantly reduced in HF compared with the no-HF control
group.
The diagnostic utility of individual miRNA biomarker candidates
was initially assessed for HF discrimination followed by differen-
tiation of HFpEF and HFrEF subtypes within the HF population
(Table 2).
Two miRNAs (miR-221 and miR-328) showed a reasonable
ability to distinguish HF from no-HF, with AUCs of 0.80 and 0.75,
respectively. Age and gender did not improve these models, but
the addition of BNP significantly improved all to AUC ∼0.90 in all
cases. Of note, using BNP alone to predict HF yielded an AUC of
0.875 (Table 3).
For distinguishing HFpEF from HFrEF, all miRNAs had an AUC
>0.7, except for miR-375 (Table 2). Both age/gender and BNP,
separately and in combination, significantly improved these mod-
els in all cases. MiR-328 and miR-375 had the greatest esti-
mated AUCs for their fully adjusted models at 0.80 and 0.82,
respectively.
Following these analyses, we investigated the impact of miRNA
biomarker combinations in predicting HF, and their ability to
differentiate HFpEF from HFrEF. In addition, with the added value
of BNP in the previous models, we also compared the diagnostic
models of miRNA combinations with and without BNP, and also
compared whether a diagnostic model using miRNAs was superior
to BNP models alone. These analyses are detailed in Table 3. In
brief, the data from Table 3 indicate that BNP is better than using
any miRNA combination as a diagnostic test for HF in general.
However, the predictive power of BNP is significantly improved
by adding any single miRNA to the analysis, with miR-221 and
miR-328 having the greatest effect, as indicated when analysed using
integrated discrimination improvement (IDI) and likelihood ratio
(LR) tests (bootstrapping and parametric methods of analysis) to
determine if one model is better at predictive probability over
another model. Using the same analytical approach, a further
improvement to the model occurs when examining the addition of
miRNA combinations with BNP. However, it is of note that when
applying a separate analysis, the 95% confidence interval (CI) for
the AUCs would indicate that either miRNAs alone (miR-328 and
miR-221) or the miRNA combinations presented are as good as
BNP in identifying HF but do not improve the model.
The utility of miRNA biomarker combinations to differentiate
HFpEF from HFrEF was investigated, and the findings are summa-
rized in Table 4 and Figure 3. According to AUC analysis, using a
single miRNA to differentiate HFpEF from HFrEF was just as good
as BNP alone. The use of a single miRNA (miR-375, −146a, −328,
or −221) with BNP compared with BNP alone can significantly
improve the model, as indicated by IDI and LR tests. The addi-
tion of miRNA combinations of two or more to BNP significantly
improves the model of BNP alone at differentiating HFpEF from
HFrEF, as evident with all forms of statistical analysis (AUC, IDI,
and LR tests).
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Identification of five microRNA (miRNA) biomarker candidates for heart failure diagnostics. miRNA biomarker discovery was
carried out using pooled serum from three cohorts: no heart failure (no-HF); heart failure with preserved ejection fraction (HFpEF); and heart
failure with reduced ejection fraction (HFrEF) (A). Five miRNA candidates, miR-30c, miR-146a, miR-221, miR-328, and miR-375, were selected
for further analysis and were subsequently quantified in the individual patients from the same discovery cohort (n= 45), by miRNA reverse
transcription–PC (RT–PCR (B–E). Data are presented in arbitrary units (AU). Bars represent fold expression changes; data represent the
mean± SEM. **P< 0.01, ***P< 0.001.
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Figure 2 Comparative expression levels of the five microRNA (miRNA) biomarker candidates within the independent validation cohort. The
circulating levels of five miRNAs (miR-30c, miR-146a, miR-221, miR-328, and miR-375) were quantified in the three study cohorts;: no heart
failure (no-HF); heart failure with preserved ejection fraction (HFpEF); and heart failure with reduced ejection fraction (HFrEF), n= 75 patients
per group. Analysis was carried out using reverse transcription–PC (RT–PCR). Data are presented in arbitrary units (AU). Data represent
mean the± SEM. *P< 0.05, **P< 0.01, ***P< 0.001.
Graphical representations of some of these examples are high-
lighted in Figure 3, with the strongest predictor consisting of a com-
bination of BNP with miR-30c, miR-221, miR-328, and miR-375,
generating an AUC of 0.854 for distinguishing HFpEF from HFrEF.
Predictive models to determine
the associations of microRNAs
with ejection fraction and left atrial
volume index
Using statistical modelling, the five miRNA biomarker candidates
were investigated to determine their relationship with the echocar-
diographic parameters EF and LAVI (Table 5). Analysis revealed that
none of the miRNAs show good R2 values for predicting EF or LAVI.
For EF, the full model including age, gender, and BNP was the best,
with 25% (combined with miR-146a or miR-221). However, BNP
alone captured almost all the explained variation in LAVI, with age
and gender making no contribution once BNP was included, and
the relationship of the miRNAs with LAVI was effectively zero. The
finding that there was no relationship between LAVI or EF and any
of the miRNAs was surprising, but this may suggest that whatever
is altering the circulating level of miRNA is independent of the clas-
sical disease mechanisms that affect EF and LAVI.
Discussion
This work provides original data on the potential role of miRNAs
as a diagnostic aid in HF and also as a tool to differentiate HFrEF ..
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. and HFpEF. The data demonstrate that the studied miRNAs are of
diagnostic utility in differentiating patients with heart failure from
asymptomatic individuals with cardiovascular risk factors. On their
own, their performance is no better than BNP but combined with
BNP they may provide better diagnostic certainty than BNP alone.
In addition, the ability of miRNAs to differentiate between HFpEF
and HFrEF is described for the first time in this study.
Five miRNA candidates were selected (miR-30c, −146a, −221,
−328, and −375) from a miRNA biomarker discovery study follow-
ing the profiling of pooled serum samples from a cohort of no-HF
patients, HFpEF patients, and HFrEF patients. When investigating
the discriminating power of these individual miRNAs to identify HF,
none of them achieved a greater AUC than BNP, which was 0.875.
However the value of the miRNAs was evident in HF diagnosis
when these were used in conjunction with BNP, and was further
improved with the addition of age and gender, generating an AUC
of ≥0.90 for all individual miRNA candidates. Similarly, the data in
Table 3 highlight that the use of miRNAs either individually or in
combinations along with BNP had a significantly better diagnos-
tic accuracy for predicting HF when compared with a BNP alone
model, with similar AUCs being generated when using miRNA
combinations of between two and five biomarkers (all >0.90).
When assessing the clinical and practical added value of increas-
ing the number of miRNAs within the combinations with the small
gain in AUC (range 0.904–0.910), a balance between diagnostic
assay costs and gain in discrimination by increasing the number of
miRNAs in the assay needs to be considered. In this case it may be
more clinically viable to use a two-miRNA combination (miR-221
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Table 2 Statistical modelling to determine the utility of individual microRNA biomarker candidates for heart failure
diagnosis and differentiation of heart failure with preserved ejection fraction and heart failure with reduced ejection
fraction subtypes
miRNA Models: AUC (95% CI)a (𝝌2 P-value)b
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No covariates BNP Age and gender BNP, age, and gender
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HF or no-HFc None – 0.88 (0.82–0.93) (P< 0.001) 0.54 (0.46–0.63) (P= 0.45) 0.91 (0.86–0.95) (P< 0.001)
miR-146a 0.68 (0.60–0.76) 0.88 (0.83–0.93) (P< 0.001) 0.67 (0.59–0.75) (P= 0.41) 0.91 (0.87–0.96) (P< 0.001)
miR-221 0.80 (0.73–0.87) 0.90 (0.85–0.95) (P< 0.001) 0.80 (0.73–0.87) (P= 0.29) 0.93 (0.88–0.97) (P< 0.001)
miR-328 0.75 (0.68–0.82) 0.88 (0.82–0.93) (P< 0.001) 0.74 (0.66–0.81) (P= 0.26) 0.91 (0.86–0.96) (P< 0.001)
miR-30c 0.71 (0.63–0.79) 0.88 (0.82–0.93) (P< 0.001) 0.68 (0.60–0.76) (P= 0.69) 0.90 (0.86–0.95) (P< 0.001)
miR-375 0.56 (0.47–0.64) 0.88 (0.82–0.93) (P< 0.001) 0.55 (0.47,0.64) (P= 0.41) 0.91 (0.86–0.96) (P< 0.001)
HFpEF or HFrEFd None – 0.65 (0.57–0.74) (P< 0.001) 0.64 (0.55–0.72) (P= 0.003) 0.68 (0.60–0.77) (P< 0.001)
miR-146a 0.57 (0.48–0.66) 0.69 (0.61–0.78) (P< 0.001) 0.69 (0.60–0.77) (P< 0.001) 0.71 (0.63–0.80) (P< 0.001)
miR-221 0.65 (0.56–0.74) 0.74 (0.66–0.82) (P< 0.001) 0.74 (0.66–0.82) (P< 0.001) 0.77 (0.69–0.85) (P< 0.001)
miR-328 0.67 (0.58–0.76) 0.78 (0.70–0.85) (P< 0.001) 0.77 (0.69–0.85) (P< 0.001) 0.80 (0.73–0.88) (P< 0.001)
miR-30c 0.51 (0.41–0.60) 0.68 (0.60,0.77) (P< 0.001) 0.66 (0.57,0.74) (P= 0.001) 0.69 (0.61,0.78) (P< 0.001)
miR-375 0.75 (0.67–0.83) 0.80 (0.73–0.87) (P< 0.001) 0.80 (0.72–0.87) (P= 0.001) 0.82 (0.75–0.89) (P< 0.001)
AUC, area under the curve; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction, HFrEF, heart failure with reduced ejection fraction; miRNA,
microRNA.
a95% CI=AUC±Z(0.975)SE. Method for estimating SE taken from Hanley and McNeil (1982).16
b𝜒2 test for difference on residual sum of squares compared with no-covariate model.
cLogistic model with full sample.
dLogistic model with heart failure only subsample.
Table 3 Comparisons of single use and combinations of microRNAs as predictors of heart failure and assessing their
value by comparing with the clinically accepted biomarker brain natriuretic peptide
Model description MicroRNA(s) AUC (95% CI)a BNP-only model comparisons
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LR test P-value IDI (95% CI)b
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Single miRNA 375 0.60 (0.51–0.68) – –
146a 0.72 (0.64–0.79) – –
30c 0.74 (0.67–0.82) – –
328 0.79 (0.72–0.86) – –
221 0.81 (0.74–0.88) – –
Two miRNA combinationc 221, 328 0.81 (0.75–0.88) – –
Three miRNA combinationc 146a, 221, 328 0.83 (0.77–0.90) – –
Four miRNA combinationc 146a, 221, 328, 30c 0.83 (0.77–0.90) – –
All miRNAs 146a, 221, 328, 375, 30c 0.84 (0.77–0.90) – –
Log (BNP) – 0.88 (0.82–0.93) – –
Log (BNP)+ single miRNA 375 0.89 (0.83–0.94) 0.004 0.030 (0.003–0.057)
146a 0.88 (0.82–0.94) 0.020 0.018 (0.000–0.035)
30c 0.89 (0.83–0.94) 0.005 0.030 (0.008–0.053)
328 0.90 (0.84–0.95) <0.001 0.053 (0.026–0.080)
221 0.90 (0.85–0.95) <0.001 0.061 (0.028–0.091)
Log (BNP)+ two miRNA combinationd 221, 375 0.90 (0.85–0.95) <0.001 0.071 (0.037–0.103)
Log (BNP)+ three miRNA combinationd 146a, 221, 375 0.91 (0.86–0.96) <0.001 0.081 (0.045–0.122)
Log (BNP)+ four miRNA combinationd 146a, 221, 328, 375 0.91 (0.86–0.96) <0.001 0.089 (0.054–0.124)
Log (BNP)+ all miRNAs 146a, 221, 328, 375, 30c 0.91 (0.86–0.96) <0.001 0.089 (0.054–0.125)
AUC, area under the curve; CI, confidence interval; IDI, integrated discrimination improvement; LR, likelihood ratio; miRNA, microRNA.
a95% CI=AUC±Z(.975)SE. Method for estimating SE taken from Hanley and McNeil 1982.16
bBootstrapped confidence interval with 1000 repetitions.
cBest model combination according to AUC.
dBest model combination according to observed IDI (see Kerr et al. 2011).17
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Table 4 Comparisons of single use and combinations of microRNAs as predictors of heart failure with preserved
ejection fraction from heart failure with preserved ejection fraction and assessing their diagnostic value by comparing
with the heart failure biomarker brain natriuretic peptide
Model description MicroRNA(s) AUC (95% CI)a BNP-only model comparisons
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LR test P-value IDI (95% CI)b
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Single miRNA 375 0.75 (0.67–0.83) – –
146a 0.57 (0.48–0.66) – –
30c 0.52 (0.42–0.61) – –
328 0.66 (0.58–0.75) – –
221 0.64 (0.55–0.73) – –
Two miRNA combinationc 30c, 375 0.76 (0.68–0.84) – –
Three miRNA combinationc 221, 328, 30c 0.79 (0.72–0.86) – –
Four miRNA combinationc 221, 328, 30c, 375 0.79 (0.72–0.87) – –
All miRNAs 146a, 221, 328, 375, 30c 0.80 (0.72–0.87) – –
Log (BNP) – 0.66 (0.58–0.75) – –
Log (BNP)+ single miRNA 375 0.78 (0.71–0.85) <0.001 0.101 (0.055–0.146)
146a 0.69 (0.61–0.78) 0.034 0.028 (0.002–0.052)
30c 0.67 (0.58–0.75) 0.529 0.003 (−0.006 to 0.011)
328 0.77 (0.70–0.85) <.001 0.118 (0.066– 0.165)
221 0.72 (0.63–0.80) 0.005 0.055 (0.016– 0.091)
Log (BNP)+ two miRNA combinationd 328, 30c 0.82 (0.75–0.89) <0.001 0.205 (0.143– 0.268)
Log (BNP)+ three miRNA combinationd 221, 328, 30c 0.84 (0.78–0.91) <0.001 0.255 (0.187–0.329)
Log (BNP)+ four miRNA combinationd 221, 328, 30c, 375 0.85 (0.79–0.92) <0.001 0.272 (0.202–0.345)
Log (BNP)+ all miRNAs 146a, 221, 328, 375, 30c 0.86 (0.79–0.92) <0.001 0.275 (0.202–0.341)
AUC, area under the curve; CI, confidence interval; IDI, integrated discrimination improvement; LR, likelihood ratio; miRNA, microRNA.
a95% CI=AUC±Z(.975)SE. Method for estimating SE taken from Hanley and McNeil 1982.16
bBootstrapped confidence interval with 1000 repetitions.
cBest model combination according to AUC.
dBest model combination according to observed IDI (see Kerr et al. 2011).17
and miR-375) with BNP, generating an AUC of 0.904 in this study,
rather than generating a diagnostic test consisting of five miRNA
components to generate an additional AUC gain of only 0.006.
When applying the five miRNA biomarker candidates individ-
ually to a model for differentiating HFpEF from HFrEF within a
symptomatic population, miR-375 yielded the highest AUC of 0.75.
All AUCs improved with the addition of BNP and age and gender,
both individually and combined, with miR-375 remaining the most
accurate diagnostically with an AUC of 0.82. When investigating
the use of miRNA biomarker panels to differentiate HFpEF from
HFrEF, combinations of two or more miRNAs was an improve-
ment on BNP alone. The best miRNA combination was found to be
miR-221, miR-328, miR-30c, and miR-375 (AUC 0.796) which gen-
erated an AUC of 0.662. Combinations of miRNAs of two or more
along with BNP yields the best AUC values and are significantly bet-
ter than using BNP on its own. The strongest predictor consisted
of a combination of BNP with miR-30c, miR-221, miR-328, and
miR-75, generating an AUC of 0.854 for distinguishing HFpEF from
HFrEF. MiRNA combinations with BNP were superior to using NPs
alone to differentiate HFpEF from HFrEF effectively.
Collectively, the data highlight that the use of miRNAs may have
the potential to be more specific than NPs for differentiating this
syndrome. .
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.. Although it was not possible to identify the cellular source
of circulating miRNAs, it is noteworthy that the five miRNA
biomarker candidates investigated herein have been described to
various degrees in other studies relating to cardiovascular disease.
In this study, all five miRNAs were reduced in HF; however miR-375
was only reduced in HFrEF. MiR-328 and miR-375 levels were
significantly different between HFpEF and HFrEF when comparing
average circulating levels.
Previous work has implicated miR-30c to have a beneficial reg-
ulatory function in myocardial matrix remodelling by negatively
regulating connective tissue growth factor, a key profibrotic pro-
tein that contributes to heart disease including pathological LV
hypertrophy.18 Increased miR-146a expression was shown to pro-
tect the myocardium from ischaemia/reperfusion injury via atten-
uation of proinflammatory pathways.19 Reduced miR-146a levels
have previously been reported in type 2 diabetes patients and
were associated with insulin resistance, poor glycaemic control,
and increased proinflammatory cytokine genes including tumour
necrosis factor 𝛼 (TNF𝛼) and interleukin 6 (IL6),20 and restor-
ing expression of miR-146 reduced extracellular matrix protein
fibronectin production and had beneficial effects in diabetes.21
An interesting study quantified miR-146a levels within circulat-
ing angiogenic cells (CACs) and plasma in an old chronic HF
population (median age 81) and showed that this miRNA was
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Receiver operating characteristic (ROC) analysis for
the use of microRNAs (miRNAs) to improve the diagnostic utility
of BNP in the differentiation of heart failure with preserved
ejection fraction (HFpEF) from heart failure with reduced ejection
fraction (HFrEF). ROC analysis highlights that the diagnostic
value of using miRNA combinations to differentiate HFpEF from
HFrEF is superior to using BNP on its own. The best diagnostic
test includes BNP with a combination of four miRNAs, namely
miR-328, miR-30c, miR-221, and miR-375, with an area under the
curve (AUC) of 0.854. ..
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.. increased 1000-fold in CACs and 2-fold in plasma compared with
an age-matched control group, and was linked to increased cellular
senescence within this cell type.22 In a recent study, Roldan et al.
have identified polymorphisms in the miR-146a gene which is linked
to increased adverse cardiovascular risk in anticoagulated patients
with AF.23 Cardiac tissue levels of miR-221 have been reported to
be deregulated during the development of hypertrophy in vivo, with
an initial decrease in expression followed by up-regulation later in
the pathogenesis.24 Detailed studies have described the impact of
increased miR-221 within the myocardium and the mechanisms
that drive the cardiomyocyte hypertrophic response.25 MiR-328
has also been implicated in the development of cardiac hypertrophy
by mechanisms involving targeting SERCA2a,26 and has been shown
to be a predictor for acute myocardial infarction, with increased
levels associated with increased risk of mortality and develop-
ment of HF.27 Finally, miR-375, which was the only down-regulated
miRNA in HFpEF patients, has been linked to diabetes, with a study
highlighting its expression in pancreatic islet cells and its require-
ment for normal pancreatic development, cell growth and prolifer-
ation, and insulin secretion.28 Circulating miR-375 levels have also
been shown to be a valuable marker to detect 𝛽-cell death and
predict diabetes in disease models.29
In summary, diagnosis of HF remains challenging, as is the abil-
ity to differentiate the subclasses which exhibit reduced or pre-
served EFs independent of echocardiography. Clinical application
of biomarkers to aid accurate and specific diagnosis appears to be
an attractive companion tool within HF care, particularly in the
community setting. Diagnostic strategies based on quantifying and
monitoring circulating miRNA levels may prove to be of clinical
value in the near future. In particular, as new therapies emerge
that are specific to HFpEF, a need for stratifying patient cohorts
for different management and treatment regimes will arise. Having
a biomarker-based diagnostic strategy may prove beneficial in this
regard.
Future direction
Although we highlight the potential diagnostic utility in the ability
of miRNAs to discriminate between symptomatic HF and asymp-
tomatic no-HF patients, it would be of significant clinical value to
determine if these miRNA biomarkers could be used to discrimi-
nate between patients with symptomatic HF and those with respi-
ratory disease such as COPD, as well as for examining the influence
of other cardiovascular factors including the impact of medications.
Patients with COPD can present with similar clinical symptoms to
HF patients, and work recently reported by Ellis and colleagues
has identified a miRNA panel combined with NT-proBNP that can
differentiate these two conditions.30
Limitations
It would be important to investigate the circulating levels of the five
miRNA candidates in a control no-HF cohort who are free from
any evidence of ventricular dysfunction in order to gain a better
appreciation of expression differences across a wider spectrum of
health and disease. In addition, expanding validation studies into
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 5 Micr RNA model results investigating the relationship between the echocardiographic parameters ejection
fraction and left atrial volume index
miRNA Models: R2 (95% CI)a (𝝌2 P-value)b
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No covariates BNP Age and gender BNP, age, and gender
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
EFc None – 0.10 (0.02–0.18) (P< 0.001) 0.08 (0.01–0.15) (P< 0.001) 0.21 (0.11–0.30) (P< 0.001)
miR-146a 0.05 (−0.01 to 0.11) 0.13 (0.04–0.21) (P< 0.001) 0.15 (0.06–0.24) (P< 0.001) 0.25 (0.15–0.35) (P< 0.001)
miR-221 0.04 (−0.01 to 0.10) 0.11 (0.03–0.19) (P< 0.001) 0.17 (0.08–0.27) (P< 0.001) 0.25 (0.15–0.35) (P< 0.001)
miR-328 0.04 (−0.01 to 0.09) 0.11 (0.03–0.18) (P< 0.001) 0.16 (0.07–0.26) (P< 0.001) 0.24 (0.14–0.34) (P< 0.001)
miR-30c 0.01 (−0.02 to 0.04) 0.10 (0.02–0.18) (P< 0.001) 0.10 (0.02–0.17) (P< 0.001) 0.22 (0.12–0.31) (P< 0.001)
miR-375 0.01 (−0.01 to 0.03) 0.11 (0.03–0.19) (P< 0.001) 0.09 (0.02–0.17) (P< 0.001) 0.22 (0.12–0.32) (P< 0.001)
LAVId None – 0.41 (0.30–0.52) (P< 0.001) 0.14 (0.05–0.23) (P< 0.001) 0.42 (0.31– 0.53) (P< 0.001)
miR-146a 0.01 (−0.02–0.05) 0.41 (0.30–0.52) (P< 0.001) 0.15 (0.05–0.24) (P< 0.001) 0.42 (0.31–0.53) (P< 0.001)
miR-221 0.04 (−0.02 to 0.10) 0.41 (0.30–0.53) (P< 0.001) 0.18 (0.08–0.28) (P< 0.001) 0.42 (0.31–0.53) (P< 0.001)
miR-328 0.01 (−0.02 to 0.04) 0.41 (0.30–0.52) (P< 0.001) 0.16 (0.06–0.25) (P< 0.001) 0.42 (0.31–0.53) (P< 0.001)
miR-30c 0.00 (−) 0.41 (0.30–0.52) (P< 0.001) 0.13 (0.04–0.22) (P< 0.001) 0.41 (0.30–0.52) (P< 0.001)
miR-375 0.00 (−) 0.42 (0.30–0.53) (P< 0.001) 0.14 (0.04–0.23) (P< 0.001) 0.42 (0.31–0.53) (P< 0.001)
CI, confidence interval LAVI, left atrial volume index; miRNA, microRNA.
a95% CI= R2d± t(0.975, n-k-1)SE. n= size of sample, k= number of predictors, Olkin–Finn method for estimating the SE.
b𝜒2 test for difference on residual sum of squares compared with no-covariate model.
cLinear model with full sample, outcome= EF2.
dLinear model with full sample, outcome= log-transformed LAVI.
larger geographically independent cohorts is necessary to test fully
the utility of these miRNA biomarker candidates. From a technical
perspective, caution needs to be exercised when undertaking
miRNA biomarker candidate discovery studies to ensure adequate
patient numbers are present in each cohort for sample pooling
prior to miRNA array analysis as this will maximize the likelihood
that findings will be maintained between data sets from discovery
arrays and individual miRNA quantification assays during validation
stages. In addition, sample pooling may result in missing potentially
useful miRNA candidates.
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